Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with ...

GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his ...

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and ...

GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.

IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.

Rutika Mehta, MD, MPH, discussed biomarker testing, PD-L1–low treatment, FLOT dosing, early referral, and ctDNA in ...

The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with ...

Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.

Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF ...

In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk ...

Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- ...

Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma. The PALISADES-1 (NCT04989803) and PALISADES-2 ...